All News
Filter News
Found 5,918 articles
-
Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694
10/26/2023
Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a global leader in epigenetics, announced today it has entered into an agreement with Cencora (formerly AmerisourceBergen) aimed at accelerating the commercialization of Zenith Epigenetics' ZEN-3694 program.
-
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
10/26/2023
Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
-
REHEVA BIOSCIENCES SUCCESSFULLY COMPLETES RH324 PHASE I CLINICAL TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER
10/25/2023
ReHeva Biosciences, a pioneering biopharmaceutical startup with the mission to help people live longer and healthier with cancer through naturally derived complex drugs, proudly announces the successful completion of its Phase I Safety Trial for its novel drug, RH324.
-
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
10/25/2023
Panbela Therapeutics, Inc today announced that an abstract about SBP-101 and CPP-1X (also known as DFMO or Eflornithine) research in multiple myeloma (cell lines), has been accepted for an online publication on the American Society of Hematology (ASH) meeting site in the November supplemental issue of the journal Blood.
-
TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
10/25/2023
TriSalus Life Sciences® Inc. announced it will present a variety of new data from its innovative clinical development pipeline at the Society for Immunotherapy of Cancer 38th Annual Meeting being held November 1-5, 2023, in San Diego, California.
-
BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate
10/25/2023
BriaCell Therapeutics Corp. is pleased to announce the formation of its medical advisory board and the appointment of three distinguished breast cancer key opinion leaders Massimo Cristofanilli, MD, FACP, Sara A. Hurvitz, MD, FACP, and Adam M. Brufsky, MD, PhD, as well as the addition of Charles Sidman, PhD, MBA, to its scientific advisory board.
-
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
10/25/2023
Carisma Therapeutics Inc. today announced that new pre-clinical data leveraging an mRNA platform to develop in-vivo chimeric antigen receptor macrophage ("CAR-M") will be presented as a late-breaking abstract (#LBA1514) at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting held from Wednesday, November 1, to Sunday, November 5, 2023, in San Diego, California.
-
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
10/24/2023
Bio-Path Holdings, Inc. announced it will host a virtual key opinion leader event to highlight the prexigebersen program and discuss advances in the treatment landscape for acute myeloid leukemia.
-
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
10/24/2023
Aprea Therapeutics, Inc. announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET. The program will feature Dr. Fiona Simpkins, Perelman School of Medicine, University of Pennsylvania, and Dr. Timothy A. Yap, University of Texas MD Anderson Cancer Center, who will discuss the current landscape of treatments and investigational drugs for patients with advanced solid tumors and their role in tumor suppression.
-
Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
10/24/2023
Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration, has joined its Scientific Advisory Board.
-
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
10/24/2023
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced treatment of the first patient in the cholangiocarcinoma cohort of the BOLSTER Trial by Dr. Ian Hu, a principal investigator of the study, at The University of Texas MD Anderson Cancer Center in Houston, Texas.
-
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
10/24/2023
Foghorn® Therapeutics Inc. (Nasdaq: FHTX) today announced that the Company will present new data from multiple preclinical and clinical programs at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting.
-
Artios Presents Positive Initial Phase 1/1b Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023
10/23/2023
Artios Pharma Limited presented promising monotherapy data from the Phase 1/1b portion of the ongoing Phase 1/2a study (NCT04657068) of its ataxia telangiectasia and Rad-3 related (“ATR”) kinase inhibitor ART0380 in advanced or metastatic solid tumors as part of a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023.
-
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
10/23/2023
Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial showed that ENHERTU® (trastuzumab deruxtecan) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2 expressing advanced solid tumors.
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
10/23/2023
Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2-expressing advanced solid tumors.
-
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav®
10/23/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new data that examine the comorbid risk of cardiovascular disease in patients with narcolepsy and idiopathic hypersomnia as well as the effect of sodium intake on cardiovascular health.
-
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
10/23/2023
NANOBIOTIX announced updated data from two presentations at the 2023 Annual Congress of the European Society for Medical Oncology.
-
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
10/23/2023
Aptose Biosciences Inc. today announced that the Company will provide a clinical update on Monday, October 30, 2023 at 8:30 AM Eastern Time, in conjunction with poster presentations at the European School of Haematology (ESH) 6th International Conference.
-
Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC
10/23/2023
Ascentage Pharma (6855.HK) announced today that it has released the latest clinical data of its dual Bcl-2/Bcl-xL inhibitor, APG-1252 (pelcitoclax), combined with osimertinib for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) in a Mini Oral at the 2023 European Society of Medical Oncology (ESMO) Congress.
-
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
10/23/2023
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information.